Evidence map›Paper›PMID 40677402›Full record

ArticleMaterials today. Bio2025

Biomimetic tumor cell membrane-camouflaged nanomicelles for synergistic chemo-immunotherapy of Triple-negative breast cancer.

Xiaoman Xu, Yunmei Song, Mingli Li, Fengxi Liu, Huiwen Zhang, Jingxia Xu, Juwei Gao, Yanna Lv, Bo Zhang, Sanjay Garg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoman XuSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, PR China.
Yunmei SongSchool of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, 5000, Australia.
Mingli LiSchool of Life Science and Engineering, Jining University, Qufu City, 273155, Shandong Province, PR China.
Fengxi LiuDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014, Shandong Province, PR China.
Huiwen ZhangSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, PR China.
Jingxia XuSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, PR China.
Juwei GaoSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, PR China.
Yanna LvSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, PR China.
Bo ZhangSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, PR China.
Sanjay GargSchool of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, 5000, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) remains a clinical challenge due to its aggressive nature. Conventional chemo-immunotherapy suffers from poor tumor targeting and systemic toxicity, necessitating advanced delivery systems for synergistic drug combinations. This study constructed a biomimetic nanodrug delivery system by coating nanomicelles with 4T1 tumor cell membranes. This strategy leverages the homologous targeting ability of tumor cell membranes to improve the accumulation of nanomicelles within TNBC tissues. The cytotoxic agent bortezomib (BTZ) and the immune modulator resiquimod (R848) were encapsulated individually and co-administered to investigate the synergistic chemo-immunotherapeutic efficacy in TNBC treatment. The biomimetic nanomicelles exhibited excellent biocompatibility and homologous targeting capacity, significantly enhancing drug delivery efficiency at the tumor site.

Indexed as

Biomimetic nanomicellesChemo-immune combination therapyHomologous targetingTriple-negative breast cancer

Identifiers

PMID40677402
PMCPMC12268940

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.